Well, at least the Poles got their science right.

Acta Biochim Pol 2001;48(1):233-40

Protective action of vitamin C against DNA damage induced by
selenium-cisplatin conjugate.

Blasiak J, Kowalik J.

Department of Molecular Genetics, University of Lodz, Poland.

Genotoxicity of anticancer drugs is of a special interest due to the risk of
inducing secondary malignancies. Vitamin C (ascorbic acid) is a recognized
antioxidant and, since human diet can be easily supplemented with vitamin C,
it seems reasonable to check whether it can protect against DNA-damaging
effects of antitumor drugs. In the present work the ability of vitamin C to
modulate cytotoxic and genotoxic effects of a cisplatin analog, conjugate
(NH3)2Pt(SeO3), in terms of cell viability, DNA damage and repair in human
lymphocytes was examined using the trypan blue exclusion test and the
alkaline comet assay, respectively. The conjugate evoked a
concentration-dependent decrease in the cell viability, reaching nearly 50%
at 250 microM. (NH3)2Pt(SeO3) at 1, 10 and 30 microM caused DNA strand
breaks, measured as the increase in the comet tail moment of the lymphocytes.
The treated cells were able to recover within a 30-min incubation in a
drug-free medium at 37 degrees C. Vitamin C at 10 and 50 microM diminished
the extent of DNA damage
evoked by (NH3)2Pt(SeO3) but had no effect on the
kinetics of DNA repair. The vitamin did not directly inactivate the
conjugate. Lymphocytes treated with endonuclease III, which recognises
oxidised pyrimidines, displayed a greater tail moment than those untreated
with the enzyme, suggesting that the damages induced by the drug have, at
least in part, an oxidative origin. Vitamin C can be considered a potential
protective agent against side effects of antitumor drugs
, but further
research with both normal and cancer cells are needed to clarify this point.